Abstract
Tumor exists as a complex network of structures with an ability to evolve and evade the host immune surveillance mechanism. The immune milieu which includes macrophages, dendritic cells, natural killer cells, neutrophils, mast cells, B cells, and T cells is found in the core, the invasive margin, or the adjacent stromal or lymphoid component of the tumor. The immune infiltrate is heterogeneous and varies within a patient and between patients of the same tumor histology. The location, density, functionality, and the crosstalk between the immune cells in the tumor microenvironment influence the nature of immune response, prognosis, and treatment outcomes in cancer patients. Therefore, an understanding of the characteristics of the immune cells and their role in tumor immune surveillance is of paramount importance to identify immune targets and to develop novel immune therapeutics in the war against cancer. In this chapter, we provide an overview of the individual components of the human immune system and the translational relevance of predictive biomarkers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Benito-Martin, A., Di Giannatale, A., Ceder, S., & Peinado, H. (2015). The new deal: A potential role for secreted vesicles in innate immunity and tumor progression. Frontiers in Immunology, 6, 66.
Murphy, K., & Weaver, C. (2016). Janeway’s immunobiology (9th ed.). Garland Science, Taylor & Francis Group, LLC.
Mellman, I. (2013). Dendritic cells: Master regulators of the immune response. Cancer Immunology Research, 1, 145–149.
Turvey, S. E., & Broide, D. H. (2010). Innate immunity. The Journal of Allergy and Clinical Immunology, 125, S24–S32.
Balkwill, F., & Mantovani, A. (2001). Inflammation and cancer: Back to Virchow? Lancet, 357, 539–545.
Janeway, C. A., Jr., & Medzhitov, R. (2002). Innate immune recognition. Annual Review of Immunology, 20, 197–216.
Finn, O. J. (2012). Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer. Annals of Oncology, 23(Suppl 8), viii6–viii9.
Lin, W. W., & Karin, M. (2007). A cytokine-mediated link between innate immunity, inflammation, and cancer. Journal of Clinical Investigation, 117, 1175–1183.
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140, 883–899.
Fedeles, B. I., Freudenthal, B. D., Yau, E., Singh, V., Chang, S. C., Li, D. Y., Delaney, J. C., Wilson, S. H., & Essigmann, J. M. (2015). Intrinsic mutagenic properties of 5-chlorocytosine: A mechanistic connection between chronic inflammation and cancer. Proceedings of the National Academy of Sciences of the United States of America, 112, E4571–E4E80.
Dvorak, H. F., Flier, J., & Frank, H. (1986). Tumors – Wounds that do not heal - similarities between tumor stroma generation and wound-healing. New England Journal of Medicine, 315, 1650–1659.
Galli, S. J., Borregaard, N., & Wynn, T. A. (2011). Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nature Immunology, 12, 1035–1044.
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009). Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell, 16, 183–194.
Mayadas, T. N., Cullere, X., & Lowell, C. A. (2014). The multifaceted functions of neutrophils. Annual Review of Pathology, 9, 181–218.
Borregaard, N. (2010). Neutrophils, from marrow to microbes. Immunity, 33, 657–670.
Kobayashi, Y. (2006). Neutrophil infiltration and chemokines. Critical Reviews in Immunology, 26, 307–315.
Scapini, P., Carletto, A., Nardelli, B., Calzetti, F., Roschke, V., Merigo, F., Tamassia, N., Pieropan, S., Biasi, D., Sbarbati, A., Sozzani, S., Bambara, L., & Cassatella, M. A. (2005). Proinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: Implications for inflammatory diseases. Blood, 105, 830–837.
Theilgaard-Monch, K., Knudsen, S., Follin, P., & Borregaard, N. (2004). The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. Journal of Immunology, 172, 7684–7693.
Fridlender, Z. G., & Albelda, S. M. (2012). Tumor-associated neutrophils: Friend or foe? Carcinogenesis, 33, 949–955.
Piccard, H., Muschel, R. J., & Opdenakker, G. (2012). On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Critical Reviews in Oncology Hematology, 82, 296–309.
Gregory, A. D., & Houghton, A. M. (2011). Tumor-associated neutrophils: New targets for Cancer therapy. Cancer Research, 71, 2411–2416.
Houghton, A. M., Rzymkiewicz, D. M., Ji, H., Gregory, A. D., Egea, E. E., Metz, H. E., Stolz, D. B., Land, S. R., Marconcini, L. A., Kliment, C. R., Jenkins, K. M., Beaulieu, K. A., Mouded, M., Frank, S. J., Wong, K. K., & Shapiro, S. D. (2010). Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nature Medicine, 16, 219–223.
Queen, M. M., Ryan, R. E., Holzer, R. G., Keller-Peck, C. R., & Jorcyk, C. L. (2005). Breast cancer cells stimulate neutrophils to produce oncostatin M: Potential implications for tumor progression. Cancer Research, 65, 8896–8904.
Acharyya, S., Oskarsson, T., Vanharanta, S., Malladi, S., Kim, J., Morris, P. G., Manova-Todorova, K., Leversha, M., Hogg, N., Seshan, V. E., Norton, L., Brogi, E., & Massague, J. (2012). A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell, 150, 165–178.
Shojaei, F., Singh, M., Thompson, J. D., & Ferrara, N. (2008). Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 105, 2640–2645.
Szczerba, B. M., Castro-Giner, F., Vetter, M., Krol, I., Gkountela, S., Landin, J., Scheidmann, M. C., Donato, C., Scherrer, R., Singer, J., Beisel, C., Kurzeder, C., Heinzelmann-Schwarz, V., Rochlitz, C., Weber, W. P., Beerenwinkel, N., & Aceto, N. (2019). Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature, 566, 553–557.
Liang, W., & Ferrara, N. (2016). The complex role of neutrophils in tumor angiogenesis and metastasis. Cancer Immunology Research, 4, 83–91.
van Gisbergen, K. P. J. M., Geijtenbeek, T. B. H., & van Kooyk, Y. (2005). Close encounters of neutrophils and DCs. Trends in Immunology, 26, 626–631.
Scapini, P., Lapinet-Vera, J. A., Gasperini, S., Calzetti, F., Bazzoni, F., & Cassatella, M. A. (2000). The neutrophil as a cellular source of chemokines. Immunological Reviews, 177, 195–203.
Chaplin, D. D. (2010). Overview of the immune response. The Journal of Allergy and Clinical Immunology, 125, S3–S23.
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Reviews, 25, 315–322.
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. The Journal of Experimental Medicine, 193, 727–740.
Duyndam, M. C., Hilhorst, M. C., Schluper, H. M., Verheul, H. M., van Diest, P. J., Kraal, G., Pinedo, H. M., & Boven, E. (2002). Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. The American Journal of Pathology, 160, 537–548.
Sica, A., Schioppa, T., Mantovani, A., & Allavena, P. (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. European Journal of Cancer, 42, 717–727.
Sica, A., Allavena, P., & Mantovani, A. (2008). Cancer related inflammation: The macrophage connection. Cancer Letters, 267, 204–215.
Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009). Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. Journal of Leukocyte Biology, 86, 1065–1073.
Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer, 4, 71–78.
Sica, A., Saccani, A., Bottazzi, B., Polentarutti, N., Vecchi, A., van Damme, J., & Mantovani, A. (2000). Autocrine production of IL-10 mediates defective IL-12 production and NF-kappa B activation in tumor-associated macrophages. Journal of Immunology, 164, 762–767.
Mantovani, A., Allavena, P., & Sica, A. (2004). Tumour-associated macrophages as a prototypic type II polarised phagocyte population: Role in tumour progression. European Journal of Cancer, 40, 1660–1667.
Tsutsui, S., Yasuda, K., Suzuki, K., Tahara, K., Higashi, H., & Era, S. (2005). Macrophage infiltration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncology Reports, 14, 425–431.
Zhang, J., Yan, Y., Yang, Y., Wang, L., Li, M., Wang, J., Liu, X., Duan, X., & Wang, J. (2016). High infiltration of tumor-associated macrophages influences poor prognosis in human gastric Cancer patients, associates with the phenomenon of EMT. Medicine (Baltimore), 95, e2636.
Hanada, T., Nakagawa, M., Emoto, A., Nomura, T., Nasu, N., & Nomura, Y. (2000). Prognostic value of tumor-associated macrophage count in human bladder cancer. International Journal of Urology, 7, 263–269.
Salvesen, H. B., & Akslen, L. A. (1999). Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. International Journal of Cancer, 84, 538–543.
Fujimoto, J., Sakaguchi, H., Aoki, I., & Tamaya, T. (2000). Clinical implications of expression of interleukin 8 related to angiogenesis in uterine cervical cancers. Cancer Research, 60, 2632–2635.
Shimura, S., Yang, G., Ebara, S., Wheeler, T. M., Frolov, A., & Thompson, T. C. (2000). Reduced infiltration of tumor-associated macrophages in human prostate cancer: Association with cancer progression. Cancer Research, 60, 5857–5861.
Forssell, J., Oberg, A., Henriksson, M. L., Stenling, R., Jung, A., & Palmqvist, R. (2007). High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clinical Cancer Research, 13, 1472–1479.
Lee, C., Bae, S. S., Joo, H., & Bae, H. (2017). Melittin suppresses tumor progression by regulating tumor-associated macrophages in a Lewis lung carcinoma mouse model. Oncotarget, 8, 54951–54965.
Lee, C., Jeong, H., Bae, Y., Shin, K., Kang, S., Kim, H., Oh, J., & Bae, H. (2019). Targeting of M2-like tumor-associated macrophages with a melittin-based pro-apoptotic peptide. Journal for Immunotherapy of Cancer, 7, 147.
Papadopoulos, K. P., Gluck, L., Martin, L. P., Olszanski, A. J., Tolcher, A. W., Ngarmchamnanrith, G., Rasmussen, E., Amore, B. M., Nagorsen, D., Hill, J. S., & Stephenson, J., Jr. (2017). First-in-human study of AMG 820, a monoclonal anti-Colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clinical Cancer Research, 23, 5703–5710.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., Colevas, A. D., O'Rourke, T., Narayanan, S., Papadopoulos, K., Fisher, G. A., Villalobos, V., Prohaska, S. S., Howard, M., Beeram, M., Chao, M. P., Agoram, B., Chen, J. Y., Huang, J., Axt, M., Liu, J., Volkmer, J. P., Majeti, R., Weissman, I. L., Takimoto, C. H., Supan, D., Wakelee, H. A., Aoki, R., Pegram, M. D., & Padda, S. K. (2019). First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. Journal of Clinical Oncology, 37, 946–953.
Fulkerson, P. C., & Rothenberg, M. E. (2013). Targeting eosinophils in allergy, inflammation and beyond. Nature Reviews. Drug Discovery, 12, 117–129.
Rothenberg, M. E., & Hogan, S. P. (2006). The eosinophil. Annual Review of Immunology, 24, 147–174.
Kita, H. (2011). Eosinophils: Multifaceted biological properties and roles in health and disease. Immunological Reviews, 242, 161–177.
Muniz, V. S., Weller, P. F., & Neves, J. S. (2012). Eosinophil crystalloid granules: Structure, function, and beyond. Journal of Leukocyte Biology, 92, 281–288.
Fernandez-Acenero, M. J., Galindo-Gallego, M., Sanz, J., & Aljama, A. (2000). Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer, 88, 1544–1548.
Dorta, R. G., Landman, G., Kowalski, L. P., Lauris, J. R. P., Latorre, M. R. D. O., & Oliveira, D. T. (2002). Tumour-associated tissue eosinophilia as a prognostic factor in oral squamous cell carcinomas. Histopathology, 41, 152–157.
Costello, R., & O'Callaghan, T. (2005). Sebahoun G: [eosinophils and antitumour response]. La Revue de Médecine Interne, 26, 479–484.
Ohkawara, Y., Lim, K. G., Xing, Z., Glibetic, M., Nakano, K., Dolovich, J., Croitoru, K., Weller, P. F., & Jordana, M. (1996). CD40 expression by human peripheral blood eosinophils. The Journal of Clinical Investigation, 97, 1761–1766.
Woerly, G., Roger, N., Loiseau, S., Dombrowicz, D., Capron, A., & Capron, M. (1999). Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): Inhibition by immunoglobulin a complexes. The Journal of Experimental Medicine, 190, 487–495.
Shi, H. Z., Humbles, A., Gerard, C., Jin, Z., & Weller, P. F. (2000). Lymph node trafficking and antigen presentation by endobronchial eosinophils. Journal of Clinical Investigation, 105, 945–953.
Lotfi, R., Herzog, G. I., DeMarco, R. A., Beer-Stolz, D., Lee, J. J., Rubartelli, A., Schrezenmeier, H., & Lotze, M. T. (2009). Eosinophils oxidize damage-associated molecular pattern molecules derived from stressed cells. Journal of Immunology, 183, 5023–5031.
Cormier, S. A., Taranova, A. G., Bedient, C., Nguyen, T., Protheroe, C., Pero, R., Dimina, D., Ochkur, S. I., O'Neill, K., Colbert, D., Lombari, T. R., Constant, S., McGarry, M. P., Lee, J. J., & Lee, N. A. (2006). Pivotal advance: Eosinophil infiltration of solid tumors is an early and persistent inflammatory host response. Journal of Leukocyte Biology, 79, 1131–1139.
Minton, K. (2015). Granulocytes: Eosinophils enable the antitumour T cell response. Nature Reviews. Immunology, 15, 333.
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hammerling, G. J. (2015). Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nature Immunology, 16, 609–617.
Munitz, A., & Hogan, S. P. (2019). Alarming eosinophils to combat tumors. Nature Immunology, 20, 250–252.
Hollande, C., Boussier, J., Ziai, J., Nozawa, T., Bondet, V., Phung, W., Lu, B., Duffy, D., Paradis, V., Mallet, V., Eberl, G., Sandoval, W., Schartner, J. M., & Pol, S. (2019). Barreira da Silva R, Albert ML: Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth. Nature Immunology, 20, 257–264.
Wei, Y. S., Zhang, X., Wang, G. Y., Zhou, Y. G., Luo, M. R., Wang, S., & Hong, C. Y. (2018). The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage ?-? Colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 14, e243–ee51.
Falcone, F. H., Zillikens, D., & Gibbs, B. F. (2006). The 21st century renaissance of the basophil? Current insights into its role in allergic responses and innate immunity. Experimental Dermatology, 15, 855–864.
Schroeder, J. T., MacGlashan, D. W., Jr., & Lichtenstein, L. M. (2001). Human basophils: Mediator release and cytokine production. Advances in Immunology, 77, 93–122.
Haas, H., Falcone, F. H., Holland, M. J., Schramm, G., Haisch, K., Gibbs, B. F., Bufe, A., & Schlaak, M. (1999). Early interleukin-4: Its role in the switch towards a Th2 response and IgE-mediated allergy. International Archives of Allergy and Immunology, 119, 86–94.
Schroeder, J. T. (2009). Basophils beyond effector cells of allergic inflammation. Advances in Immunology, 101, 123–161.
Prevete, N., Staiano, R. I., Granata, F., Detoraki, A., Necchi, V., Ricci, V., Triggiani, M., De Paulis, A., Marone, G., & Genovese, A. (2013). Expression and function of angiopoietins and their tie receptors in human basophils and mast cells. Journal of Biological Regulators Homeostatic Agents, 27, 827–839.
De Monte, L., Wormann, S., Brunetto, E., Heltai, S., Magliacane, G., Reni, M., Paganoni, A. M., Recalde, H., Mondino, A., Falconi, M., Aleotti, F., Balzano, G., Ul, H. A., Doglioni, C., & Protti, M. P. (2016). Basophil recruitment into tumor-draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic Cancer patients. Cancer Research, 76, 1792–1803.
Frossi, B., De Carli, M., & Pucillo, C. (2004). The mast cell: An antenna of the microenvironment that directs the immune response. Journal of Leukocyte Biology, 75, 579–585.
Qi, X., Hong, J., Chaves, L., Zhuang, Y., Chen, Y., Wang, D., Chabon, J., Graham, B., Ohmori, K., Li, Y., & Huang, H. (2013). Antagonistic regulation by the transcription factors C/EBPalpha and MITF specifies basophil and mast cell fates. Immunity, 39, 97–110.
Marone, G., Galli, S. J., & Kitamura, Y. (2002). Probing the roles of mast cells and basophils in natural and acquired immunity, physiology and disease. Trends in Immunology, 23, 425–427.
Galli, S. J., & Franco, C. B. (2008). Basophils are back! Immunity, 28, 495–497.
Stone, K. D., Prussin, C., & Metcalfe, D. D. (2010). IgE, mast cells, basophils, and eosinophils. The Journal of Allergy and Clinical Immunology, 125, S73–S80.
Metcalfe, D. D. (2008). Mast cells and mastocytosis. Blood, 112, 946–956.
Nonomura, N., Takayama, H., Nishimura, K., Oka, D., Nakai, Y., Shiba, M., Tsujimura, A., Nakayama, M., Aozasa, K., & Okuyama, A. (2007). Decreased number of mast cells infiltrating into needle biopsy specimens leads to a better prognosis of prostate cancer. British Journal of Cancer, 97, 952–956.
Rojas, I. G., Spencer, M. L., Martinez, A., Maurelia, M. A., & Rudolph, M. I. (2005). Characterization of mast cell subpopulations in lip cancer. Journal of Oral Pathology & Medicine, 34, 268–273.
Fukushima, H., Ohsawa, M., Ikura, Y., Naruko, T., Sugama, Y., Suekane, T., Kitabayashi, C., Inoue, T., Hino, M., & Ueda, M. (2006). Mast cells in diffuse large B-cell lymphoma; their role in fibrosis. Histopathology, 49, 498–505.
Kormelink, T. G., Abudukelimu, A., & Redegeld, F. A. (2009). Mast cells as target in Cancer therapy. Current Pharmaceutical Design, 15, 1868–1878.
Ribatti, D., Vacca, A., Nico, B., Crivellato, E., Roncali, L., & Dammacco, F. (2001). The role of mast cells in tumour angiogenesis. British Journal of Haematology, 115, 514–521.
Rajput, A. B., Turbin, D. A., Cheang, M. C., Voduc, D. K., Leung, S., Gelmon, K. A., Gilks, C. B., & Huntsman, D. G. (2008). Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: A study of 4,444 cases. Breast Cancer Research and Treatment, 107, 249–257.
Chan, J. K., Magistris, A., Loizzi, V., Lin, F., Rutgers, J., Osann, K., DiSaia, P. J., & Samoszuk, M. (2005). Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecologic Oncology, 99, 20–25.
Welsh, T. J., Green, R. H., Richardson, D., Waller, D. A., O'Byrne, K. J., & Bradding, P. (2005). Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. Journal of Clinical Oncology, 23, 8959–8967.
Tan, S. Y., Fan, Y., Luo, H. S., Shen, Z. X., Guo, Y., & Zhao, L. J. (2005). Prognostic significance of cell infiltrations of immunosurveillance in colorectal cancer. World Journal of Gastroenterology, 11, 1210–1214.
Latti, S., Leskinen, M., Shiota, N., Wang, Y. F., Kovanen, P. T., & Lindstedt, K. A. (2003). Mast cell-mediated apoptosis of endothelial cells in vitro: A paracrine mechanism involving TNF-alpha-mediated down-regulation of bcl-2 expression. Journal of Cellular Physiology, 195, 130–138.
Leskinen, M. J., Lindstedt, K. A., Wang, Y. F., & Kovanen, P. T. (2003). Mast cell chymase induces smooth muscle cell apoptosis by a mechanism involving fibronectin degradation and disruption of focal adhesions. Arteriosclerosis Thrombosis Vascular Biology, 23, 238–243.
Hammer, G. E., & Ma, A. (2013). Molecular control of steady-state dendritic cell maturation and immune homeostasis. Annual Review of Immunology, 31, 743–791.
Liu, K., & Nussenzweig, M. C. (2010). Origin and development of dendritic cells. Immunological Reviews, 234, 45–54.
Liu, K., Victora, G. D., Schwickert, T. A., Guermonprez, P., Meredith, M. M., Yao, K., Chu, F. F., Randolph, G. J., Rudensky, A. Y., & Nussenzweig, M. (2009). In vivo analysis of dendritic cell development and homeostasis. Science, 324, 392–397.
Shortman, K., & Naik, S. H. (2007). Steady-state and inflammatory dendritic-cell development. Nature Reviews. Immunology, 7, 19–30.
Trombetta, E. S., & Mellman, I. (2005). Cell biology of antigen processing in vitro and in vivo. Annual Review of Immunology, 23, 975–1028.
Steinman, R. M. (2012). Decisions about dendritic cells: Past, present, and future. Annual Review of Immunology, 30, 1–22.
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019). Dendritic cells in cancer immunology and immunotherapy. Nature Reviews. Immunology.
Spranger, S., Bao, R., & Gajewski, T. F. (2015). Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature, 523, 231–235.
Bottcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Sousa, C. R. E. (2018). NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting Cancer immune control. Cell, 172, 1022.
Ljunggren, H. G., & Karre, K. (1990). In search of the missing self - Mhc molecules and Nk cell recognition. Immunology Today, 11, 237–244.
Vivier, E., Nunes, J. A., & Vely, F. (2004). Natural killer cell signaling pathways. Science, 306, 1517–1519.
Tomasello, E., Blery, M., Vely, F., & Vivier, E. (2000). Signaling pathways engaged by NK cell receptors: Double concerto for activating receptors, inhibitory receptors and NK cells. Seminars in Immunology, 12, 139–147.
Strengell, M., Matikainen, S., Siren, J., Lehtonen, A., Foster, D., Julkunen, I., & Sareneva, T. (2003). IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. Journal of Immunology, 170, 5464–5469.
Brady, J., Carotta, S., Thong, R. P., Chan, C. J., Hayakawa, Y., Smyth, M. J., & Nutt, S. L. (2010). The interactions of multiple cytokines control NK cell maturation. Journal of Immunology, 185, 6679–6688.
Lunemann, A., Lunemann, J. D., & Munz, C. (2009). Regulatory NK-cell functions in inflammation and autoimmunity. Molecular Medicine, 15, 352–358.
Becknell, B., & Caligiuri, M. A. (2008). Natural killer cells in innate immunity and cancer. Journal of Immunotherapy, 31, 685–692.
Kaiser, B. K., Yim, D., Chow, I. T., Gonzalez, S., Dai, Z., Mann, H. H., Strong, R. K., Groh, V., & Spies, T. (2007). Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature, 447, 482–486.
Groh, V., Wu, J., Yee, C., & Spies, T. (2002). Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature, 419, 734–738.
Castriconi, R., Cantoni, C., Della Chiesa, M., Vitale, M., Marcenaro, E., Conte, R., Biassoni, R., Bottino, C., Moretta, L., & Moretta, A. (2003). Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 4120–4125.
Sconocchia, G., Titus, J. A., & Segal, D. M. (1997). Signaling pathways regulating CD44-dependent cytolysis in natural killer cells. Blood, 90, 716–725.
Wang, W., Erbe, A. K., Hank, J. A., Morris, Z. S., & Sondel, P. M. (2015). NK cell-mediated antibody-dependent cellular cytotoxicity in Cancer immunotherapy. Frontiers in Immunology, 6, 368.
Ferlazzo, G., Thomas, D., Lin, S. L., Goodman, K., Morandi, B., Muller, W. A., Moretta, A., & Munz, C. (2004). The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. Journal of Immunology, 172, 1455–1462.
Sun, J. C., Beilke, J. N., & Lanier, L. L. (2009). Adaptive immune features of natural killer cells. Nature, 457, 557–561.
Albertsson, P. A., Basse, P. H., Hokland, M., Goldfarb, R. H., Nagelkerke, J. F., Nannmark, U., & Kuppen, P. J. (2003). NK cells and the tumour microenvironment: Implications for NK-cell function and anti-tumour activity. Trends in Immunology, 24, 603–609.
Mensali, N., Dillard, P., Hebeisen, M., Lorenz, S., Theodossiou, T., Myhre, M. R., Fane, A., Gaudernack, G., Kvalheim, G., Myklebust, J. H., Inderberg, E. M., & Walchli, S. (2019). NK cells specifically TCR-dressed to kill cancer cells. eBioMedicine, 40, 106–117.
Liu, E. L., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Kerbauy, L. N., Overman, B., Thall, P., Kaplan, M., Nandivada, V., Kaur, I., Cortes, A. N., Cao, K., Daher, M., Hosing, C., Cohen, E. N., Kebriaei, P., Mehta, R., Neelapu, S., Nieto, Y., Wang, M., Wierda, W., Keating, M., Champlin, R., Shpall, E. J., & Rezvani, K. (2020). Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. New England Journal of Medicine, 382, 545–553.
Robey, E., & Fowlkes, B. J. (1994). Selective events in T cell development. Annual Review of Immunology, 12, 675–705.
Germain, R. N. (2002). T-cell development and the CD4-CD8 lineage decision. Nature Reviews. Immunology, 2, 309–322.
Scollay, R., Wilson, A., D'Amico, A., Kelly, K., Egerton, M., Pearse, M., Wu, L., & Shortman, K. (1988). Developmental status and reconstitution potential of subpopulations of murine thymocytes. Immunological Reviews, 104, 81–120.
Blackburn, C. C., & Manley, N. R. (2004). Developing a new paradigm for thymus organogenesis. Nature Reviews. Immunology, 4, 278–289.
Vonboehmer, H., Teh, H. S., & Kisielow, P. (1989). The Thymus selects the useful, neglects the useless and destroys the harmful. Immunology Today, 10, 57–61.
Leung, R. K., Thomson, K., Gallimore, A., Jones, E., Van den Broek, M., Sierro, S., Alsheikhly, A. R., McMichael, A., & Rahemtulla, A. (2001). Deletion of the CD4 silencer element supports a stochastic mechanism of thymocyte lineage commitment. Nature Immunology, 2, 1167–1173.
Sharma, P., Wagner, K., Wolchok, J. D., & Allison, J. P. (2011). Novel cancer immunotherapy agents with survival benefit: Recent successes and next steps. Nature Reviews. Cancer, 11, 805–812.
Lugo-Villarino, G., Maldonado-Lopez, R., Possemato, R., Penaranda, C., & Glimcher, L. H. (2003). T-bet is required for optimal production of IFN-gamma and antigen-specific T cell activation by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 100, 7749–7754.
Zhu, J. F., Guo, L. Y., Watson, C. J., Hu-Li, J., & Paul, W. E. (2001). Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. Journal of Immunology, 166, 7276–7281.
Zhou, L., Lopes, J. E., & Chong, M. M. (2008). Ivanov, II, min R, Victora GD, Shen Y, Du J, Rubtsov YP, Rudensky AY, Ziegler SF, Littman DR: TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature, 453, 236–240.
Chen, W. J., Jin, W. W., Hardegen, N., Lei, K. J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003). Conversion of peripheral CD4(+)CD25(−) naive T cells to CD4(+)CD25(+) regulatory T cells by TGF-beta induction of transcription factor Foxp3. The Journal of Experimental Medicine, 198, 1875–1886.
Nurieva, R. I., Chung, Y., Hwang, D., Yang, X. O., Kang, H. S., Ma, L., Wang, Y. H., Watowich, S. S., Jetten, A. M., Tian, Q., & Dong, C. (2008). Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity, 29, 138–149.
Staudt, V., Bothur, E., Klein, M., Lingnau, K., Reuter, S., Grebe, N., Gerlitzki, B., Hoffmann, M., Ulges, A., Taube, C., Dehzad, N., Becker, M., Stassen, M., Steinborn, A., Lohoff, M., Schild, H., Schmitt, E., & Bopp, T. (2010). Interferon-regulatory factor 4 is essential for the developmental program of T helper 9 cells. Immunity, 33, 192–202.
Saule, P., Trauet, J., Dutriez, V., Lekeux, W., Dessaint, J. P., & Labalette, M. (2006). Accumulation of memory T cells from childhood to old age: Central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mechanisms of Ageing and Development, 127, 274–281.
Kabelitz, D., Serrano, R., Kouakanou, L., Peters, C., & Kalyan, S. (2020). Cancer immunotherapy with gammadelta T cells: Many paths ahead of us. Cellular & Molecular Immunology, 17, 925–939.
Chen, L., & Flies, D. B. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nature Reviews. Immunology, 13, 227–242.
Linsley, P. S., Clark, E. A., & Ledbetter, J. A. (1990). T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proceedings of the National Academy of Sciences of the United States of America, 87, 5031–5035.
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999). ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature, 397, 263–266.
Nam, K. O., Kang, H., Shin, S. M., Cho, K. H., Kwon, B., Kwon, B. S., Kim, S. J., & Lee, H. W. (2005). Cross-linking of 4-1BB activates TCR-signaling pathways in CD8+ T lymphocytes. Journal of Immunology, 174, 1898–1905.
Godfrey, W. R., Fagnoni, F. F., Harara, M. A., Buck, D., & Engleman, E. G. (1994). Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. The Journal of Experimental Medicine, 180, 757–762.
Vonderheide, R. H. (2007). Prospect of targeting the CD40 pathway for cancer therapy. Clinical Cancer Research, 13, 1083–1088.
Nocentini, G., & Riccardi, C. (2009). GITR: A modulator of immune response and inflammation. Advances in Experimental Medicine and Biology, 647, 156–173.
Marin-Acevedo, J. A., Dholaria, B., Soyano, A. E., Knutson, K. L., Chumsri, S., & Lou, Y. (2018). Next generation of immune checkpoint therapy in cancer: New developments and challenges. Journal of Hematology & Oncology, 11, 39.
Ruby, C. E., Yates, M. A., Hirschhorn-Cymerman, D., Chlebeck, P., Wolchok, J. D., Houghton, A. N., Offner, H., & Weinberg, A. D. (2009). Cutting edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of Immunology, 183, 4853–4857.
Vonderheide, R. H., & Glennie, M. J. (2013). Agonistic CD40 antibodies and cancer therapy. Clinical Cancer Research, 19, 1035–1043.
Linsley, P. S., Brady, W., Urnes, M., Grosmaire, L. S., Damle, N. K., & Ledbetter, J. A. (1991). CTLA-4 is a second receptor for the B cell activation antigen B7. The Journal of Experimental Medicine, 174, 561–569.
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., Horton, H. F., Fouser, L., Carter, L., Ling, V., Bowman, M. R., Carreno, B. M., Collins, M., Wood, C. R., & Honjo, T. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. The Journal of Experimental Medicine, 192, 1027–1034.
Buchbinder, E. I., & Desai, A. (2016). CTLA-4 and PD-1 pathways similarities, differences, and implications of their inhibition. American Journal of Clinical Oncology-Cancer Clinical Trials, 39, 98–106.
Liang, S. C., Latchman, Y. E., Buhlmann, J. E., Tomczak, M. F., Horwitz, B. H., Freeman, G. J., & Sharpe, A. H. (2003). Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. European Journal of Immunology, 33, 2706–2716.
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001). PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proceedings of the National Academy of Sciences of the United States of America, 98, 13866–13871.
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016). Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity, 44, 989–1004.
Joller, N., Lozano, E., Burkett, P. R., Patel, B., Xiao, S., Zhu, C., Xia, J., Tan, T. G., Sefik, E., Yajnik, V., Sharpe, A. H., Quintana, F. J., Mathis, D., Benoist, C., Hafler, D. A., & Kuchroo, V. K. (2014). Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses. Immunity, 40, 569–581.
Jordan, M. S., Boesteanu, A., Reed, A. J., Petrone, A. L., Holenbeck, A. E., Lerman, M. A., Naji, A., & Caton, A. J. (2001). Thymic selection of CD4(+)CD25(+) regulatory T cells induced by an agonist self-peptide. Nature Immunology, 2, 301–306.
Croft, M. (2009). The role of TNF superfamily members in T-cell function and diseases. Nature Reviews. Immunology, 9, 271–285.
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews. Cancer, 12, 252–264.
Nagasawa, T. (2006). Microenvironmental niches in the bone marrow required for B-cell development. Nature Reviews. Immunology, 6, 107–116.
Hardy, R. R., Carmack, C. E., Shinton, S. A., Kemp, J. D., & Hayakawa, K. (1991). Resolution and characterization of pro-B and pre-pro-B cell stages in normal mouse bone marrow. The Journal of Experimental Medicine, 173, 1213–1225.
Tiegs, S. L., Russell, D. M., & Nemazee, D. (1993). Receptor editing in self-reactive bone marrow B cells. The Journal of Experimental Medicine, 177, 1009–1020.
Carsetti, R., Kohler, G., & Lamers, M. C. (1995). Transitional B cells are the target of negative selection in the B cell compartment. The Journal of Experimental Medicine, 181, 2129–2140.
Pieper, K., Grimbacher, B., & Eibel, H. (2013). B-cell biology and development. The Journal of Allergy and Clinical Immunology, 131, 959–971.
Shlomchik, M. J., & Weisel, F. (2012). Germinal center selection and the development of memory B and plasma cells. Immunological Reviews, 247, 52–63.
Schroeder, H. W., Jr., & Cavacini, L. (2010). Structure and function of immunoglobulins. The Journal of Allergy and Clinical Immunology, 125, S41–S52.
Lipman, N. S., Jackson, L. R., Trudel, L. J., & Weis-Garcia, F. (2005). Monoclonal versus polyclonal antibodies: Distinguishing characteristics, applications, and information resources. ILAR Journal, 46, 258–268.
Kung, P., Goldstein, G., Reinherz, E. L., & Schlossman, S. F. (1979). Monoclonal antibodies defining distinctive human T cell surface antigens. Science, 206, 347–349.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., & Oi, V. T. (1984). Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains. Proceedings of the National Academy of Sciences of the United States of America, 81, 6851–6855.
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988). Reshaping human antibodies for therapy. Nature, 332, 323–327.
Harding, F. A., Stickler, M. M., Razo, J., & DuBridge, R. B. (2010). The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs, 2, 256–265.
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012). Antibody therapy of cancer. Nature Reviews. Cancer, 12, 278–287.
Wennhold, K., Shimabukuro-Vornhagen, A., & von Bergwelt-Baildon, M. (2019). B cell-based cancer immunotherapy. Transfusion Medicine and Hemotherapy, 46, 36–46.
Elgueta, R., Benson, M. J., de Vries, V. C., Wasiuk, A., Guo, Y. X., & Noelle, R. J. (2009). Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunological Reviews, 229, 152–172.
Fridman, W. H., Pages, F., Sautes-Fridman, C., & Galon, J. (2012). The immune contexture in human tumours: Impact on clinical outcome. Nature Reviews. Cancer, 12, 298–306.
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The three Es of cancer immunoediting. Annual Review of Immunology, 22, 329–360.
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunology, 3, 991–998.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57–70.
Teng, M. W., Galon, J., Fridman, W. H., & Smyth, M. J. (2015). From mice to humans: Developments in cancer immunoediting. The Journal of Clinical Investigation, 125, 3338–3346.
Mellman, I., Coukos, G., & Dranoff, G. (2011). Cancer immunotherapy comes of age. Nature, 480, 480–489.
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012). Coordinated regulation of myeloid cells by tumours. Nature Reviews. Immunology, 12, 253–268.
Huang, B., Pan, P. Y., Li, Q. S., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S. H. (2006). Gr-1(+)CD115(+) immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Research, 66, 1123–1131.
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013). The immunosuppressive tumour network: Myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138, 105–115.
Waldmann, T. A. (2018). Cytokines in Cancer immunotherapy. Cold Spring Harbor Perspectives in Biology, 10.
Bentebibel, S. E., Hurwitz, M. E., Bernatchez, C., Haymaker, C., Hudgens, C. W., Kluger, H. M., Tetzlaff, M. T., Tagliaferri, M. A., Zalevsky, J., Hoch, U., Fanton, C., Aung, S., Hwu, P., Curti, B. D., Tannir, N. M., Sznol, M., & Diab, A. (2019). A first-in-human study and biomarker analysis of NKTR-214, a novel 1L2R beta gamma-biased cytokine, in patients with advanced or metastatic solid tumors. Cancer Discovery, 9, 711–721.
Diab, A., Tykodi, S., Curti, B., Cho, D., Wong, M., Puzanov, I., Lewis, K., Maio, M., Daniels, G., Spira, A., Tagliaferri, M., Hannah, A., Clemens, W., Imperiale, M., Bernatchez, C., Haymaker, C., Bentebibel, S., Zalevsky, J., Hoch, U., Fanton, C., Rizwan, A., Aung, S., Cattaruzza, F., Iaccucci, E., Sawka, D., Bilen, M., Lorigan, P. C., Grignani, G., Larkin, J., Jang, S., Warzocha, E., Sznol, M., & Hurwitz, M. (2018). 33rd annual meeting & pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2018). Journal for Immunotherapy of Cancer, 6, 115.
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., Sheppard, C., Hong, K., Cutler, C., Turner, S., LaFace, D., Kleinschek, M., Judo, M., Ayanoglu, G., Langowski, J., Gu, D., Paporello, B., Murphy, E., Sriram, V., Naravula, S., Desai, B., Medicherla, S., Seghezzi, W., McClanahan, T., Cannon-Carlson, S., Beebe, A. M., & Oft, M. (2011). IL-10 elicits IFNgamma-dependent tumor immune surveillance. Cancer Cell, 20, 781–796.
Naing, A., Papadopoulos, K. P., Autio, K. A., Ott, P. A., Patel, M. R., Wong, D. J., Falchook, G. S., Pant, S., Whiteside, M., Rasco, D. R., Mumm, J. B., Chan, I. H., Bendell, J. C., Bauer, T. M., Colen, R. R., Hong, D. S., Van Vlasselaer, P., Tannir, N. M., Oft, M., & Infante, J. R. (2016). Safety, antitumor activity, and immune activation of Pegylated recombinant human Interleukin-10 (AM0010) in patients with advanced solid tumors. Journal of Clinical Oncology, 34, 3562–3569.
Wong, D., Schneider, J. G., Aljumaily, R., Korn, W. M., Infante, J., Patel, M., Autio, K., Papadopoulos, K., Naing, A., Gabrail, N. Y., Munster, P., Goldman, J., Ratti, N., Van Vlasselaer, P., Hung, A., Oft, M., & Garon, E. (2017). 9PDPEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC. Annals of Oncology, 28.
Hecht, J. R., Naing, A., Falchook, G. S., Patel, M. R., Infante, J. R., Aljumaily, R., Wong, D. J. L., Autio, K. A., Wainberg, Z. A., Javle, M. M., Bendell, J. C., Pant, S., Hung, A., Vlasselaer, P. V., Oft, M., & Papadopoulos, K. P. (2018). Overall survival of PEGylated human IL-10 (AM0010) with 5-FU/LV and oxaliplatin (FOLFOX) in metastatic pancreatic adenocarcinoma (PDAC). Journal of Clinical Oncology, 36, 374.
Naing, A., Infante, J. R., Papadopoulos, K. P., Chan, I. H., Shen, C., Ratti, N. P., Rojo, B., Autio, K. A., Wong, D. J., Patel, M. R., Ott, P. A., Falchook, G. S., Pant, S., Hung, A., Pekarek, K. L., Wu, V., Adamow, M., McCauley, S., Mumm, J. B., Wong, P., Van Vlasselaer, P., Leveque, J., Tannir, N. M., & Oft, M. (2018). PEGylated IL-10 (Pegilodecakin) induces systemic immune activation, CD8(+) T cell invigoration and polyclonal T cell expansion in Cancer patients. Cancer Cell, 34, 775–791. e3.
Kumari, N., Dwarakanath, B. S., Das, A., & Bhatt, A. N. (2016). Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biology, 37, 11553–11572.
Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018). Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nature Reviews. Clinical Oncology, 15, 234–248.
Waugh, D. J., & Wilson, C. (2008). The interleukin-8 pathway in cancer. Clinical Cancer Research, 14, 6735–6741.
Schalper, K. A., Carleton, M., Zhou, M., Chen, T., Feng, Y., Huang, S. P., Walsh, A. M., Baxi, V., Pandya, D., Baradet, T., Locke, D., Wu, Q. Y., Reilly, T. P., Phillips, P., Nagineni, V., Gianino, N., Gu, J. L., Zhao, H. Y., Perez-Gracia, J. L., Sanmamed, M. F., & Melero, I. (2020). Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nature Medicine, 26, 688.
Bilusic, M., Heery, C. R., Collins, J. M., Donahue, R. N., Palena, C., Madan, R. A., Karzai, F., Marte, J. L., Strauss, J., Gatti-Mays, M. E., Schlom, J., & Gulley, J. L. (2019). Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. Journal for Immunotherapy of Cancer, 7, 240.
Nguyen, K. G., Vrabel, M. R., Mantooth, S. M., Hopkins, J. J., Wagner, E. S., Gabaldon, T. A., & Zaharoff, D. A. (2020). Localized Interleukin-12 for Cancer immunotherapy. Frontiers in Immunology, 11, 575597.
Hurteau, J. A., Blessing, J. A., DeCesare, S. L., & Creasman, W. T. (2001). Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: A gynecologic oncology group study. Gynecologic Oncology, 82, 7–10.
Motzer, R. J., Rakhit, A., Thompson, J. A., Nemunaitis, J., Murphy, B. A., Ellerhorst, J., Schwartz, L. H., Berg, W. J., & Bukowski, R. M. (2001). Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. Journal of Interferon & Cytokine Research, 21, 257–263.
Strauss, J., Heery, C. R., Kim, J. W., Jochems, C., Donahue, R. N., Montgomery, A. S., McMahon, S., Lamping, E., Marte, J. L., Madan, R. A., Bilusic, M., Silver, M. R., Bertotti, E., Schlom, J., & Gulley, J. L. (2019). First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clinical Cancer Research, 25, 99–109.
Greaney, S. K., Algazi, A. P., Tsai, K. K., Takamura, K. T., Chen, L., Twitty, C. G., Zhang, L., Paciorek, A., Pierce, R. H., Le, M. H., Daud, A. I., & Fong, L. (2020). Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and Intratumoral T-cell responses. Cancer Immunology Research, 8, 246–254.
Algazi, A., Bhatia, S., Agarwala, S., Molina, M., Lewis, K., Faries, M., Fong, L., Levine, L. P., Franco, M., Oglesby, A., Ballesteros-Merino, C., Bifulco, C. B., Fox, B. A., Bannavong, D., Talia, R., Browning, E., Le, M. H., Pierce, R. H., Gargosky, S., Tsai, K. K., Twitty, C., & Daud, A. I. (2020). Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients. Annals of Oncology, 31, 532–540.
Algazi, A. P., Twitty, C. G., Tsai, K. K., Le, M., Pierce, R., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., Francisco, M., Fong, L., Pittet, M. J., Arlauckas, S. P., Garris, C., Levine, L. P., Bifulco, C., Ballesteros-Merino, C., Bhatia, S., Gargosky, S., Andtbacka, R. H. I., Fox, B. A., Rosenblum, M. D., & Daud, A. I. (2020). Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma. Clinical Cancer Research, 26, 2827–2837.
Fabbi, M., Carbotti, G., & Ferrini, S. (2017). Dual roles of IL-27 in Cancer biology and immunotherapy. Mediators of Inflammation, 2017, 3958069.
Murugaiyan, G., & Saha, B. (2013). IL-27 in tumor immunity and immunotherapy. Trends in Molecular Medicine, 19, 108–116.
Zhu, J., Liu, J. Q., Shi, M., Cheng, X., Ding, M., Zhang, J. C., Davis, J. P., Varikuti, S., Satoskar, A. R., Lu, L., Pan, X., Zheng, P., Liu, Y., & Bai, X. F. (2018). IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy. JCI Insight, 3.
Waldmann, T. A., Miljkovic, M. D., & Conlon, K. C. (2020). Interleukin-15 (dys)regulation of lymphoid homeostasis: Implications for therapy of autoimmunity and cancer. The Journal of Experimental Medicine, 217.
Conlon, K. C., Lugli, E., Welles, H. C., Rosenberg, S. A., Fojo, A. T., Morris, J. C., Fleisher, T. A., Dubois, S. P., Perera, L. P., Stewart, D. M., Goldman, C. K., Bryant, B. R., Decker, J. M., Chen, J., Worthy, T. A., Figg, W. D., Sr., Peer, C. J., Sneller, M. C., Lane, H. C., Yovandich, J. L., Creekmore, S. P., Roederer, M., & Waldmann, T. A. (2015). Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. Journal of Clinical Oncology, 33, 74–82.
Conlon, K. C., Potter, E. L., Pittaluga, S., Lee, C. R., Miljkovic, M. D., Fleisher, T. A., Dubois, S., Bryant, B. R., Petrus, M., Perera, L. P., Hsu, J., Figg, W. D., Peer, C. J., Shih, J. H., Yovandich, J. L., Creekmore, S. P., Roederer, M., & Waldmann, T. A. (2019). IL15 by continuous intravenous infusion to adult patients with solid tumors in a phase I trial induced dramatic NK-cell subset expansion. Clinical Cancer Research, 25, 4945–4954.
Waldmann, T. A., Dubois, S., Miljkovic, M. D., & Conlon, K. C. (2020). IL-15 in the combination immunotherapy of Cancer. Frontiers in Immunology, 11, 868.
Tarhini, A. A., Millward, M., Mainwaring, P., Kefford, R., Logan, T., Pavlick, A., Kathman, S. J., Laubscher, K. H., Dar, M. M., & Kirkwood, J. M. (2009). A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer, 115, 859–868.
Zhou, T., Damsky, W., Weizman, O. E., McGeary, M. K., Hartmann, K. P., Rosen, C. E., Fischer, S., Jackson, R., Flavell, R. A., Wang, J., Sanmamed, M. F., Bosenberg, M. W., & Ring, A. M. (2020). IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature, 583, 609.
Khan, Z., Hammer, C., Guardino, E., Chandler, G. S., & Albert, M. L. (2019). Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach. Genome Medicine, 11.
Johnson, D., Patel, A. B., Uemura, M. I., Trinh, V., Jackson, N., Zobniw, C. M., Tetzlaff, M. T., Hwu, P., Curry, J. L., & Diab, A. (2019). IL17A blockade successfully treated Psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunology Research, 7, 860–865.
Abu-Sbeih, H., Ali, F. S., Wang, X. M., Mallepally, N., Chen, E., Altan, M., Bresalier, R. S., Charabaty, A., Dadu, R., Jazaeri, A., Lashner, B., & Wang, Y. H. (2019). Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. Journal for Immunotherapy of Cancer, 7.
Tangri, S., LiCalsi, C., Sidney, J., & Sette, A. (2002). Rationally engineered proteins or antibodies with absent or reduced immunogenicity. Current Medicinal Chemistry, 9, 2191–2199.
Weiner, L. M., Surana, R., & Wang, S. Z. (2010). Monoclonal antibodies: Versatile platforms for cancer immunotherapy. Nature Reviews. Immunology, 10, 317–327.
Krummel, M. F., & Allison, J. P. (1995). Cd28 and Ctla-4 have opposing effects on the response of T-cells to stimulation. Journal of Experimental Medicine, 182, 459–465.
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbe, C., Peschel, C., Quirt, I., Clark, J. I., Wolchok, J. D., Weber, J. S., Tian, J., Yellin, M. J., Nichol, G. M., Hoos, A., & Urba, W. J. (2010). Improved survival with Ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363, 711–723.
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., Gilson, M. M., Wang, C., Selby, M., Taube, J. M., Anders, R., Chen, L., Korman, A. J., Pardoll, D. M., Lowy, I., & Topalian, S. L. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology, 28, 3167–3175.
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., Barlesi, F., Kohlhaufl, M., Arrieta, O., Burgio, M. A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D. E., Gettinger, S. N., Rudin, C. M., Rizvi, N., Crino, L., Blumenschein, G. R., Jr., Antonia, S. J., Dorange, C., Harbison, C. T., Graf Finckenstein, F., & Brahmer, J. R. (2015). Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. The New England Journal of Medicine, 373, 1627–1639.
Brahmer, J., Reckamp, K. L., Baas, P., Crino, L., Eberhardt, W. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Aren Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R. (2015). Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung Cancer. The New England Journal of Medicine, 373, 123–135.
Herbst, R. S., Baas, P., Kim, D. W., Felip, E., Perez-Gracia, J. L., Han, J. Y., Molina, J., Kim, J. H., Arvis, C. D., Ahn, M. J., Majem, M., Fidler, M. J., de Castro, G., Jr., Garrido, M., Lubiniecki, G. M., Shentu, Y., Im, E., Dolled-Filhart, M., & Garon, E. B. (2015). Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet.
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O’Donnell, P. H., Balmanoukian, A., Loriot, Y., Srinivas, S., Retz, M. M., Grivas, P., Joseph, R. W., Galsky, M. D., Fleming, M. T., Petrylak, D. P., Perez-Gracia, J. L., Burris, H. A., … Dreicer, R. (2016). Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet, 387, 1909–1920.
U.S. Food and Drug Administration. (2018). Hematology/Oncology (Cancer) approvals & safety notifications.
Aspeslagh, S., Postel-Vinay, S., Rusakiewicz, S., Soria, J. C., Zitvogel, L., & Marabelle, A. (2016). Rationale for anti-OX40 cancer immunotherapy. European Journal of Cancer, 52, 50–66.
Topalian, S. L., Weiner, G. J., & Pardoll, D. M. (2011). Cancer immunotherapy comes of age. Journal of Clinical Oncology, 29, 4828–4836.
Wargo, J. A., Cooper, Z. A., & Flaherty, K. T. (2014). Universes collide: Combining immunotherapy with targeted therapy for cancer. Cancer Discovery, 4, 1377–1386.
Sullivan, R. J., Gonzalez, R., Lewis, K. D., Hamid, O., Infante, J. R., Patel, M. R., Hodi, F. S., Wallin, J., Pitcher, B., Cha, E., Roberts, L., Ballinger, M., & Hwu, P. (2017). Atezolizumab (a) + cobimetinib (C) + vemurafenib (V) in BRAFV600-mutant metastatic melanoma (mel): Updated safety and clinical activity. Journal of Clinical Oncology, 35, 3063.
Formenti, S. C., & Demaria, S. (2013). Combining radiotherapy and cancer immunotherapy: A paradigm shift. Journal of the National Cancer Institute, 105, 256–265.
Golden, E. B., Chachoua, A., Fenton-Kerimian, M. B., Demaria, S., & Formenti, S. C. (2015). Abscopal responses in metastatic non-small cell lung Cancer (NSCLC) patients treated on a phase 2 study of combined radiation therapy and Ipilimumab: Evidence for the in situ vaccination hypothesis of radiation. International Journal of Radiation Oncology Biology Physics, 93, S66–SS7.
Fiorica, F., Belluomini, L., Stefanelli, A., Santini, A., Urbini, B., Giorgi, C., & Frassoldati, A. (2018). Immune checkpoint inhibitor Nivolumab and radiotherapy in pretreated lung Cancer patients: Efficacy and safety of combination. American Journal of Clinical Oncology.
Moon, Y. W., Hajjar, J., Hwu, P., & Naing, A. (2015). Targeting the indoleamine 2,3-dioxygenase pathway in cancer. Journal for Immunotherapy of Cancer, 3, 51.
Koblish, H. K., Hansbury, M. J., Bowman, K. J., Yang, G., Neilan, C. L., Haley, P. J., Burn, T. C., Waeltz, P., Sparks, R. B., Yue, E. W., Combs, A. P., Scherle, P. A., Vaddi, K., & Fridman, J. S. (2010). [INCB preclin] Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors. Molecular Cancer Therapeutics, 9, 489–498.
Liu, X., Shin, N., Koblish, H. K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M. J., Thomas, B., Rupar, M., Waeltz, P., Bowman, K. J., Polam, P., Sparks, R. B., Yue, E. W., Li, Y., Wynn, R., Fridman, J. S., Burn, T. C., Combs, A. P., Newton, R. C., & Scherle, P. A. (2010). [INCB preclin] selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood, 115, 3520–3530.
Metz, R., Rust, S., Duhadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012). [Indoximod preclin] IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology, 1, 1460–1468.
Iversen, T. Z., Engell-Noerregaard, L., Ellebaek, E., Andersen, R., Larsen, S. K., Bjoern, J., Zeyher, C., Gouttefangeas, C., Thomsen, B. M., Holm, B., Straten, P. T., Mellemgaard, A., Andersen, M. H., & Svane, I. M. (2013). [IDO pep vac] Long-lasting disease stabilization in the absence of toxicity in metastatic lung Cancer patients vaccinated with an epitope derived from Indoleamine 2,3 dioxygenase. Clinical Cancer Research.
Siu, L. L., Gelmon, K., Chu, Q., Pachynski, R., Alese, O., Basciano, P., Walker, J., Mitra, P., Zhu, L., Phillips, P., Hunt, J., & Desai, J. (2017). Abstract CT116: BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial. Cancer Research, 77, CT116-CT.
Mautino, M. R., Jaipuri, F. A., Waldo, J., Kumar, S., Adams, J., Allen, C. V., Marcinowicz-Flick, A., Munn, D., Vahanian, N., & Link, C. J. J. (2013). NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. In AACR, p. 491.
Long, G. V., Dummer, R., Hamid, O., Gajewski, T. F., Caglevic, C., Dalle, S., Arance, A., Carlino, M. S., Grob, J. J., Kim, T. M., Demidov, L., Robert, C., Larkin, J., Anderson, J. R., Maleski, J., Jones, M., Diede, S. J., & Mitchell, T. C. (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): A phase 3, randomised, double-blind study. The Lancet Oncology, 20, 1083–1097.
Choi, Y., Shi, Y., Haymaker, C. L., Naing, A., Ciliberto, G., & Hajjar, J. (2020). T-cell agonists in cancer immunotherapy. Journal for Immunotherapy of Cancer, 8.
Segal, N. H., Logan, T. F., Hodi, F. S., McDermott, D., Melero, I., Hamid, O., Schmidt, H., Robert, C., Chiarion-Sileni, V., Ascierto, P. A., Maio, M., Urba, W. J., Gangadhar, T. C., Suryawanshi, S., Neely, J., Jure-Kunkel, M., Krishnan, S., Kohrt, H., Sznol, M., & Levy, R. (2017). Results from an integrated safety analysis of Urelumab, an agonist anti-CD137 monoclonal antibody. Clinical Cancer Research, 23, 1929–1936.
Tolcher, A. W., Sznol, M., Hu-Lieskovan, S., Papadopoulos, K. P., Patnaik, A., Rasco, D. W., Di Gravio, D., Huang, B., Gambhire, D., Chen, Y., Thall, A. D., Pathan, N., Schmidt, E. V., & Chow, L. Q. M. (2017). Phase Ib study of Utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in combination with Pembrolizumab (MK-3475) in patients with advanced solid tumors. Clinical Cancer Research, 23, 5349–5357.
Zheng, L., Judkins, C., Hoare, J., Klein, R., Parkinson, R., Wang, H., Cao, H., Durham, J., Purtell. K., Jesus-Acosta, A., Le, D., Narang, A., Anders, R., Burkhart, R., Burns, W., Wolfgang, C., Thompson, E., Laheru, D., He, J., & Jaffee, E. (2020). Urelumab (anti-CD137 agonist) in combination with vaccine and nivolumab treatments is safe and associated with pathologic response as neoadjuvant and adjuvant therapy for resectable pancreatic cancer [abstract 812]. Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting & Preconference Programs (SITC 2020).
Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z. P., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017). Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40. Clinical Cancer Research, 23, 6165–6177.
Young, K. H., Baird, J. R., Savage, T., Cottam, B., Friedman, D., Bambina, S., Messenheimer, D. J., Fox, B., Newell, P., Bahjat, K. S., Gough, M. J., & Crittenden, M. R. (2016). Optimizing timing of immunotherapy improves control of tumors by Hypofractionated radiation therapy. PLoS One, 11, e0157164.
Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., & Zhang, D. (2011). Activation of toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Research, 71, 2466–2475.
Wolska, A., Lech-Maranda, E., & Robak, T. (2009). Toll-like receptors and their role in carcinogenesis and anti-tumor treatment. Cellular & Molecular Biology Letters, 14, 248–272.
Liu, Y., Yan, W., Tohme, S., Chen, M., Fu, Y., Tian, D., Lotze, M., Tang, D. L., & Tsung, A. (2015). Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through toll-like receptor 9. Journal of Hepatology, 63, 114–121.
Shi, M., Chen, X., Ye, K., Yao, Y., & Li, Y. (2016). Application potential of toll-like receptors in cancer immunotherapy: Systematic review. Medicine, 95.
Li, K., Qu, S., Chen, X., Wu, Q., & Shi, M. (2017). Promising targets for Cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. International Journal of Molecular Sciences, 18.
Ishikawa, H., Ma, Z., & Barber, G. N. (2009). STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity. Nature, 461, 788–792.
Fuertes, M. B., Kacha, A. K., Kline, J., Woo, S. R., Kranz, D. M., Murphy, K. M., & Gajewski, T. F. (2011). Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. The Journal of Experimental Medicine, 208, 2005–2016.
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S. R., Lemmens, E., Banda, T., Leong, J. J., Metchette, K., Dubensky, T. W., Jr., & Gajewski, T. F. (2015). Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports, 11, 1018–1030.
Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., Sivick, K. E., Zeng, Q., Soares, K. C., Zheng, L., Portnoy, D. A., Woodward, J. J., Pardoll, D. M., Dubensky, T. W., & Kim, Y. (2015). STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Science Translational Medicine, 7.
Deng, L. F., Liang, H., Xu, M., Yang, X. M., Burnette, B., Arina, A., Li, X. D., Mauceri, H., Beckett, M., Darga, T., Huang, X. N., Gajewski, T. F., Chen, Z. J. J., Fu, Y. X., & Weichselbaum, R. R. (2014). STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity, 41, 843–852.
Biswas, S. K., & Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nature Immunology, 11, 889–896.
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., Jones, T., Jucknischke, U., Scheiblich, S., Kaluza, K., Gorr, I. H., Walz, A., Abiraj, K., Cassier, P. A., Sica, A., Gomez-Roca, C., de Visser, K. E., Italiano, A., Le Tourneau, C., Delord, J. P., Levitsky, H., Blay, J. Y., & Ruttinger, D. (2014). Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for Cancer therapy. Cancer Cell, 25, 846–859.
Song, M. L., Liu, T., Shi, C. R., Zhang, X. Z., & Chen, X. Y. (2016). Bioconjugated manganese dioxide nanoparticles enhance chemotherapy response by priming tumor-associated macrophages toward M1-like phenotype and attenuating tumor hypoxia. ACS Nano, 10, 633–647.
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., Coussens, L. M., & Daldrup-Link, H. E. (2016). Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nature Nanotechnology, 11, 986–994.
Wiehagen, K. R., Girgis, N. M., Yamada, D. H., Smith, A. A., Chan, S. R., Grewal, I. S., Quigley, M., & Verona, R. I. (2017). Combination of CD40 Agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity. Cancer Immunology Research, 5, 1109–1121.
Hibbs, J. B., Taintor, R. R., & Vavrin, Z. (1987). Macrophage cytotoxicity - role for L-arginine deiminase and Imino-nitrogen oxidation to nitrite. Science, 235, 473–476.
Rodriguez, P. C., Quiceno, D. G., Zabaleta, J., Ortiz, B., Zea, A. H., Piazuelo, M. B., Delgado, A., Correa, P., Brayer, J., Sotomayor, E. M., Antonia, S., Ochoa, J. B., & Ochoa, A. C. (2004). Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Research, 64, 5839–5849.
Munder, M. (2009). Arginase: An emerging key player in the mammalian immune system. British Journal of Pharmacology, 158, 638–651.
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews. Cancer, 16, 275–287.
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021). PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology.
U.S. Food and Drug Administration. (2015) FDA approves Keytruda for advanced non-small cell lung cancer. Edited by http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm465444.htm.
Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., Kohrt, H. E., Horn, L., Lawrence, D. P., Rost, S., Leabman, M., Xiao, Y., Mokatrin, A., Koeppen, H., Hegde, P. S., Mellman, I., Chen, D. S., & Hodi, F. S. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 515, 563–567.
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., Cortinovis, D. L., Leach, J., Polikoff, J., Barrios, C., Kabbinavar, F., Frontera, O. A., De Marinis, F., Turna, H., Lee, J. S., Ballinger, M., Kowanetz, M., He, P., Chen, D. S., Sandler, A., Gandara, D. R., & Grp, O. S. (2017). Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet, 389, 255–265.
Madore, J., Vilain, R. E., Menzies, A. M., Kakavand, H., Wilmott, J. S., Hyman, J., Yearley, J. H., Kefford, R. F., Thompson, J. F., Long, G. V., Hersey, P., & Scolyer, R. A. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28.
Rosell, R., & Palmero, R. (2015). PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors. Cancer Biology & Medicine, 12, 71–73.
Sharma, P., & Allison, J. P. (2015). The future of immune checkpoint therapy. Science, 348, 56–61.
Hadrup, S., Donia, M., & Thor Straten, P. (2013). Effector CD4 and CD8 T cells and their role in the tumor microenvironment. Cancer Microenvironment, 6, 123–133.
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., Rubin, S. C., & Coukos, G. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. The New England Journal of Medicine, 348, 203–213.
Ruffini, E., Asioli, S., Filosso, P. L., Lyberis, P., Bruna, M. C., Macri, L., Daniele, L., & Oliaro, A. (2009). Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. The Annals of Thoracic Surgery, 87, 365–371. discussion 71–2.
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., & Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 10, 942–949.
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., Biota, C., Doffin, A. C., Durand, I., Olive, D., Perez, S., Pasqual, N., Faure, C., Coquard, I. R., Puisieux, A., Caux, C., Blay, J. Y., & Menetrier-Caux, C. (2009). Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and Lead to an adverse clinical outcome. Cancer Research, 69, 2000–2009.
Fu, J. L., Xu, D. P., Liu, Z. W., Shi, M., Zhao, P., Fu, B. Y., Zhang, Z., Yang, H. Y., Zhang, H., Zhou, C. B., Ya, J. X., Jin, L., Wang, H. F., Yang, Y. P., Fu, Y. X., & Wang, F. S. (2007). Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology, 132, 2328–2339.
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H. N., Wang, H., Luber, B. S., Zhang, M., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., Sears, C. L., Anders, R. A., Pardoll, D. M., & Housseau, F. (2015). The vigorous immune microenvironment of microsatellite instable Colon Cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discovery, 5, 43–51.
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoue, F., Bruneval, P., Cugnenc, P. H., Trajanoski, Z., Fridman, W. H., & Pages, F. (2006). Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science, 313, 1960–1964.
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, A. N., Carmona, M., Kivork, C., Seja, E., Cherry, G., Gutierrez, A. J., Grogan, T. R., Mateus, C., Tomasic, G., Glaspy, J. A., Emerson, R. O., Robins, H., Pierce, R. H., Elashoff, D. A., Robert, C., & Ribas, A. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515, 568–571.
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gomez, H., Bastholt, L., Chasalow, S. D., & Berman, D. (2011). A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine, 9.
Martens, A., Wistuba-Hamprecht, K., Yuan, J., Postow, M. A., Wong, P., Capone, M., Madonna, G., Khammari, A., Schilling, B., Sucker, A., Schadendorf, D., Martus, P., Dreno, B., Ascierto, P. A., Wolchok, J. D., Pawelec, G., Garbe, C., & Weide, B. (2016). Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with Ipilimumab. Clinical Cancer Research, 22, 4848–4858.
Perez-Romero, K., Rodriguez, R. M., Amedei, A., Barcelo-Coblijn, G., & Lopez, D. H. (2020). Immune landscape in tumor microenvironment: Implications for biomarker development and immunotherapy. International Journal of Molecular Sciences, 21.
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015). Classifying cancers based on T-cell infiltration and PD-L1. Cancer Research, 75, 2139–2145.
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., Nagtegaal, I. D., Palmqvist, R., Masucci, G. V., Botti, G., Tatangelo, F., Delrio, P., Maio, M., Laghi, L., Grizzi, F., Asslaber, M., D’Arrigo, C., Vidal-Vanaclocha, F., Zavadova, E., Chouchane, L., Ohashi, P. S., Hafezi-Bakhtiari, S., Wouters, B. G., Roehrl, M., Nguyen, L., Kawakami, Y., Hazama, S., Okuno, K., Ogino, S., Gibbs, P., Waring, P., Sato, N., Torigoe, T., Itoh, K., Patel, P. S., Shukla, S. N., Wang, Y. L., Kopetz, S., Sinicrope, F. A., Scripcariu, V., Ascierto, P. A., Marincola, F. M., Fox, B. A., & Pages, F. (2014). Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. Journal of Pathology, 232, 199–209.
Mlecnik, B., Van den Eynde, M., Bindea, G., Church, S. E., Vasaturo, A., Fredriksen, T., Lafontaine, L., Haicheur, N., Marliot, F., Debetancourt, D., Pairet, G., Jouret-Mourin, A., Gigot, J. F., Hubert, C., Danse, E., Dragean, C., Carrasco, J., Humblet, Y., Valge-Archer, V., Berger, A., Pages, F., Machiels, J. P., & Galon, J. (2018). Comprehensive Intrametastatic immune quantification and major impact of Immunoscore on survival. Journal of the National Cancer Institute, 110.
Pagès, F., Mlecnik, B., Marliot, F., Bindea, G., Ou, F.-S., Bifulco, C., Lugli, A., Zlobec, I., Rau, T. T., Berger, M. D., Nagtegaal, I. D., Vink-Börger, E., Hartmann, A., Geppert, C., Kolwelter, J., Merkel, S., Grützmann, R., Van den Eynde, M., Jouret-Mourin, A., … Galon, J. (2018). International validation of the consensus immunoscore for the classification of colon cancer: A prognostic and accuracy study. The Lancet, 391(10135), 2128–2139.
Haymaker, C. L., Kim, D., Uemura, M., Vence, L. M., Phillip, A., McQuail, N., Brown, P. D., Fernandez, I., Hudgens, C. W., Creasy, C., Hwu, W. J., Sharma, P., Tetzlaff, M. T., Allison, J. P., Hwu, P., Bernatchez, C., & Diab, A. (2017). Metastatic melanoma patient had a complete response with clonal expansion after whole brain radiation and PD-1 blockade. Cancer Immunology Research, 5, 100–105.
Olugbile, S., Park, J.-H., Hoffman, P., Szeto, L., Patel, J., Vigneswaran, W. T., Vokes, E., Nakamura, Y., & Klyotani, K. (2017). Sustained Oligoclonal T cell expansion correlates with durable response to immune checkpoint blockade in lung cancer. Journal of Cancer Science & Therapy, 9, 717–722.
Inoue, H., Park, J. H., Kiyotani, K., Zewde, M., Miyashita, A., Jinnin, M., Kiniwa, Y., Okuyama, R., Tanaka, R., Fujisawa, Y., Kato, H., Morita, A., Asai, J., Katoh, N., Yokota, K., Akiyama, M., Ihn, H., Fukushima, S., & Nakamura, Y. (2016). Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma. Oncoimmunology, 5.
Looney, T. J., Topacio-Hall, D., Lowman, G., Conroy, J., Morrison, C., Oh, D., Fong, L., & Zhang, L. (2019). TCR convergence in individuals treated with immune checkpoint inhibition for Cancer. Frontiers in Immunology, 10, 2985.
Tang, X., Huang, Y., Lei, J., Luo, H., & Zhu, X. (2019). The single-cell sequencing: New developments and medical applications. Cell & Bioscience, 9, 53.
Gibellini, L., De Biasi, S., Porta, C., Lo Tartaro, D., Depenni, R., Pellacani, G., Sabbatini, R., & Cossarizza, A. (2020). Single-cell approaches to profile the response to immune checkpoint inhibitors. Frontiers in Immunology, 11, 490.
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J. D., Wong, P., Ho, T. S., Miller, M. L., Rekhtman, N., Moreira, A. L., Ibrahim, F., Bruggeman, C., Gasmi, B., Zappasodi, R., Maeda, Y., Sander, C., Garon, E. B., Merghoub, T., Wolchok, J. D., Schumacher, T. N., & Chan, T. A. (2015). Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348, 124–128.
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., Hollmann, T. J., Bruggeman, C., Kannan, K., Li, Y., Elipenahli, C., Liu, C., Harbison, C. T., Wang, L., Ribas, A., Wolchok, J. D., & Chan, T. A. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. The New England Journal of Medicine, 371, 2189–2199.
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., Seja, E., Lomeli, S., Kong, X., Kelley, M. C., Sosman, J. A., Johnson, D. B., Ribas, A., & Lo, R. S. (2016). Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell, 165, 35–44.
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., de la Chapelle, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R. H., Wood, L. D., Cuka, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Zhou, S., Cornish, T. C., Taube, J. M., Anders, R. A., Eshleman, J. R., Vogelstein, B., & Diaz, L. A., Jr. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. The New England Journal of Medicine, 372, 2509–2520.
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. V., Bignell, G. R., Bolli, N., Borg, A., Borresen-Dale, A. L., Boyault, S., Burkhardt, B., Butler, A. P., Caldas, C., Davies, H. R., Desmedt, C., Eils, R., Eyfjord, J. E., Foekens, J. A., … Stratton, M. R. (2013). Signatures of mutational processes in human cancer. Nature, 500, 415–421.
Lastwika, K. J., Wilson, W., Li, Q. K., Norris, J., Xu, H. Y., Ghazarian, S. R., Kitagawa, H., Kawabata, S., Taube, J. M., Yao, S., Liu, L. N., Gills, J. J., & Dennis, P. A. (2016). Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Research, 76, 227–238.
Ribas, A., Robert, C., Hodi, F. S., Wolchok, J. D., Joshua, A. M., Hwu, W. J., Weber, J. S., Zarour, H. M., Kefford, R., Loboda, A., Albright, A., Kang, S. P., Ebbinghaus, S., Yearley, J., Murphy, E., Nebozhyn, M., Lunceford, J. K., McClanahan, T., Ayers, M., & Daud, A. (2015). Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. Journal of Clinical Oncology, 33.
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Albright, A., Cheng, J., Kang, S. P., Ebbinghaus, S., Yearley, J., Shankaran, V., Seiwert, T., Ribas, A., & McClanahan, T. (2015). Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors. Journal for Immunotherapy of Cancer, 3, 80.
Higgs, B. W., Morehouse, C., Streicher, K., Rebelatto, M. C., Steele, K., Jin, X., Pilataxi, F., Brohawn, P. Z., Blake-Haskins, J. A., Gupta, A. K., & Ranade, K. (2016). Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients. Journal of Clinical Oncology, 34, 3036.
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., Braiteh, F., Waterkamp, D., He, P., Zou, W., Chen, D. S., Yi, J., Sandler, A., Rittmeyer, A., & Group, P. S. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387, 1837–1846.
Blank, C. U., Haanen, J. B., Ribas, A., & Schumacher, T. N. (2016). Cancer immunology. The cancer “immunogram”. Science, 352, 658–660.
Karasaki, T., Nagayama, K., Kuwano, H., Nitadori, J. I., Sato, M., Anraku, M., Hosoi, A., Matsushita, H., Morishita, Y., Kashiwabara, K., Takazawa, M., Ohara, O., Kakimi, K., & Nakajima, J. (2017). An Immunogram for the Cancer-immunity cycle: Towards personalized immunotherapy of lung Cancer. Journal of Thoracic Oncology, 12, 791–803.
Martens, A., Wistuba-Hamprecht, K., Geukes Foppen, M., Yuan, J., Postow, M. A., Wong, P., Romano, E., Khammari, A., Dreno, B., Capone, M., Ascierto, P. A., Di Giacomo, A. M., Maio, M., Schilling, B., Sucker, A., Schadendorf, D., Hassel, J. C., Eigentler, T. K., Martus, P., Wolchok, J. D., Blank, C., Pawelec, G., Garbe, C., & Weide, B. (2016). Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab. Clinical Cancer Research, 22, 2908–2918.
Hopkins, A. M., Rowland, A., Kichenadasse, G., Wiese, M. D., Gurney, H., McKinnon, R. A., Karapetis, C. S., & Sorich, M. J. (2017). Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. British Journal of Cancer, 117, 913–920.
Manson, G., Norwood, J., Marabelle, A., Kohrt, H., & Houot, R. (2016). Biomarkers associated with checkpoint inhibitors. Annals of Oncology, 27, 1199–1206.
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013). Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: An early increase in lymphocyte and eosinophil counts is associated with improved survival. Annals of Oncology, 24, 1697–1703.
Ku, G. Y., Yuan, J. D., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010). Single-institution experience with Ipilimumab in advanced melanoma patients in the compassionate use setting lymphocyte count after 2 doses correlates with survival. Cancer, 116, 1767–1775.
Wilgenhof, S., Du Four, S., Vandenbroucke, F., Everaert, H., Salmon, I., Lienard, D., Marmol, V. D., & Neyns, B. (2013). Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma. Journal of Immunotherapy, 36, 215–222.
Di Giacomo, A. M., Danielli, R., Calabro, L., Bertocci, E., Nannicini, C., Giannarelli, D., Balestrazzi, A., Vigni, F., Riversi, V., Miracco, C., Biagioli, M., Altomonte, M., & Maio, M. (2011). Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunology Immunotherapy, 60, 467–477.
Simeone, E., Gentilcore, G., Giannarelli, D., Grimaldi, A. M., Caraco, C., Curvietto, M., Esposito, A., Paone, M., Palla, M., Cavalcanti, E., Sandomenico, F., Petrillo, A., Botti, G., Fulciniti, F., Palmieri, G., Queirolo, P., Marchetti, P., Ferraresi, V., Rinaldi, G., Pistillo, M. P., Ciliberto, G., Mozzillo, N., & Ascierto, P. A. (2014). Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma. Cancer Immunology Immunotherapy, 63, 675–683.
Gebhardt, C., Sevko, A., Jiang, H. H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., Schadendorf, D., Utikal, J., & Umansky, V. (2015). Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clinical Cancer Research, 21, 5453–5459.
Kelderman, S., Heemskerk, B., van Tinteren, H., van den Brom, R. R., Hospers, G. A., van den Eertwegh, A. J., Kapiteijn, E. W., de Groot, J. W., Soetekouw, P., Jansen, R. L., Fiets, E., Furness, A. J., Renn, A., Krzystanek, M., Szallasi, Z., Lorigan, P., Gore, M. E., Schumacher, T. N., Haanen, J. B., Larkin, J. M., & Blank, C. U. (2014). Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunology, Immunotherapy, 63, 449–458.
Lee, J. H., Long, G. V., Boyd, S., Lo, S., Menzies, A. M., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R. A., Mann, G. J., Kefford, R. F., Carlino, M. S., & Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28, 1130–1136.
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., Behera, M., Wu, H., McCausland, M., Chen, Z. J., Zhang, C., Khuri, F. R., Owonikoko, T. K., Ahmed, R., & Ramalingam, S. S. (2017). Proliferation of PD-1+CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 114, 4993–4998.
Shaikh, F. Y., Gills, J. J., & Sears, C. L. (2019). Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma. eBioMedicine, 48, 642–647.
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., Cogdill, A. P., Zhao, L., Hudgens, C. W., Hutchinson, D. S., Manzo, T., de Macedo, M. P., Cotechini, T., Kumar, T., Chen, W. S., … Wargo, J. A. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science, 359, 97–103.
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y. Y., Alegre, M. L., Luke, J. J., & Gajewski, T. F. (2018). The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science, 359, 104.
Hajjar, J., Mendoza, T., Zhang, L. L., Fu, S. Q., Piha-Paul, S. A., Hong, D. S., Janku, F., Karp, D. D., Ballhausen, A., Gong, J., Zarifa, A., Peterson, C. B., Meric-Bernstam, F., Jenq, R., & Naing, A. (2021). Associations between the gut microbiome and fatigue in cancer patients. Scientific Reports, 11.
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Horn, L., Drake, C. G., Pardoll, D. M., Chen, L., Sharfman, W. H., Anders, R. A., … Sznol, M. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England Journal of Medicine, 366, 2443–2454.
Alban, T. J., & Chan, T. A. (2021). Immunotherapy biomarkers: The long and winding road. Nature Reviews Clinical Oncology.
Litchfield, K. R., Reading, J., McGranahan, N., Quezada, S., & Swanton, C. (2020). Meta-analysis of tumour and T cell intrinsic mechanisms of sensitization to checkpoint inhibition. Annals of Oncology, 31, S1092-S.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Stephen, B., Hajjar, J. (2021). Immune System in Action. In: Naing, A., Hajjar, J. (eds) Immunotherapy. Advances in Experimental Medicine and Biology, vol 1342. Springer, Cham. https://doi.org/10.1007/978-3-030-79308-1_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-79308-1_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-79307-4
Online ISBN: 978-3-030-79308-1
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)